RxDoctor Payments Data

Angela Scott, MD

Ophthalmology · Brunswick, GANPI 1679502934

Payments from drug & device makers

$2,363in general payments, 2019–2025

Across 82 payments — averaging $28.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$1K
  • AbbVie$248
  • Amgen$231
  • Johnson & Johnson Surgical Vision, Inc.$145
  • Sun Pharmaceutical Industries Inc.$105
  • Carl Zeiss Meditec, Inc.$79
  • plus $525 from 16 others

What the payments were for

  • Travel & lodging$76632%
  • Food & beverage$1,59768%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,363 in reported general payments places this provider in the 50th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$434,049
Medicare patients
1,274
Services billed
4,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine64$88,515
LumiganBimatoprost62$34,008
Cyclosporine24$22,070
RhopressaNetarsudil Mesylate26$11,079
VyzultaLatanoprostene Bunod11$7,789
Latanoprost621$7,544
Loteprednol Etabonate23$6,193
Brimonidine Tartrate315$4,859
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat326$4,473
RocklatanNetarsudil Mesylat/Latanoprost11$4,447
Prednisolone Acetate68$4,081
Timolol Maleate302$3,665
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,333
Dorzolamide Hcl140$1,965
ValacyclovirValacyclovir Hcl19$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$248$122,524126 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$28$15,52637 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$35$6,19323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →